survival and/or locoregional recurrence, and made recommendations about adjuvant treatment based on these groups. Patients at highest risk are those with positive margins and/or extracapsular spread (ECS) outside of lymph nodes. 8 In The goal of this study was to identify national trends in the use of postoperative adjuvant treatment for surgically treated T1 and T2
OPSCC. Specifically, we sought to understand how often postoperative CRT is recommended based on guideline risk factor groups, as well as how often and to whom it is actually given.
| MATERIALS AND METHODS

| Data source
The data source for this study was the National Cancer Database (NCDB), which is a joint program of the Commission on Cancer (CoC) and the American College of Surgeons (ACS). 12 The NCDB is a hospital-based registry that collects data from over 70% of new cancer cases in the United States each year, and over 80% of cases from the oral cavity and pharynx. 13 It is best used for assessing processes of care such as treatment trends. 14 The source files were used in accordance with the NCDB Participant User Files (PUF) data use agreement. This study was given IRB waiver by Memorial Sloan Kettering Cancer Center.
| Study cohort
We identified all patients with clinically staged T1 and T2 OPSCC diagnosed between 2004 and 2013 who were ≥18 years old. We included International Classification of Disease for Oncology (ICD-O) codes for the oropharynx (ICDO C019, C090, C091, C098, C099, C100, C101, C102, C103, C104, C108, C109, C142). We included only patients with histologically proven SCC tissue examined by microscope rather than cytology alone; the tissue could be examined from biopsy or surgical pathology specimens. We excluded patients who had received part or all of their treatment outside of the NCDB reporting facility, whose treatment information was missing or for whom the sequence of treatments was not clear, and whose staging information was inconsistent with treatment information or could not be assessed (Fig. 1) .
We then selected patients who underwent a primary surgical approach as initial treatment. Primary surgical patients were those who underwent more than a "local tumor excision" before any radiation or chemotherapy. For tonsil and other oropharynx all categories of "pharyngectomy" were used. Base of tongue tumors (ICD C019) are listed with other tongue tumors; primary surgical patients were those who underwent at least "glossectomy." After selecting FIGURE 1 Flow diagram of patient inclusion/exclusion primary surgical patients we excluded those who had incomplete information on margin status and ECS (Fig. 1 ).
| Outcomes
The outcome variable of interest was the use of postoperative CRT among patients undergoing primary surgery for T1-T2 OPSCC. 3 | RESULTS
| Characteristics of the cohort
We identified 4833 patients who presented with T1-T2 OPSCC between 2004 and 2013, underwent primary surgical therapy, and had complete pathologic information for analysis ( Table 1 ). The majority were male (78%), age 50-64 (56%), and were white (92%). The majority had private insurance (69%) and zero comorbidities on the CharlsonDeyo index (81%). More than half (59%) were treated at academic cancer programs. While 31% were treated at high volume hospitals that saw >50 patients with OPSCC, 28% were treated at very low volume hospitals where only 10 or fewer patients with OPSCC were treated over the study period. Regarding tumor factors, 25% of patients treated with primary surgery had positive margins, and 24% had ECS.
| Postoperative CRT
Overall 44% (2120) Table 1 Column 2). Patients were more likely to receive postoperative CRT if they were younger, male, white, had private or no insurance compared to government insurance, and had fewer comorbidities (P < 0.0001 for all; Table 1 Column 2). Patients were more likely to receive postoperative CRT if they were treated at community hospitals compared to academic hospitals (52% vs 38%, P < 0.0001), and at the lowest volume hospitals compared to the highest volume hospitals (52% vs 40%, P < 0.0001; Table 1 Column 2).
| Tumor risk factor groups
Of the total of 2120 patients who received postoperative CRT, 62% and/or pT3-T4 but no ECS, negative margins); of these, 46% received postoperative CRT. An additional 31% (1479) of patients undergoing primary surgery had no apparent pathologic risk factors (no ECS, negative margins, pT1-T2, and N0-N1); of these, 16% received postoperative CRT.
| Hospital level variation
When examined according to risk factor group and the hospital where they were treated, patients were more likely to receive postoperative CRT if they went to community hospitals or very low volume hospitals, regardless of whether they had high risk pathologic factors or no apparent risk factors (Fig. 3) . Wide variation can be seen across hospital types in hospitals' provision of postoperative CRT among all patients (Fig. 4A) , and among patients with high risk factors or no apparent risk factors (Fig. 4B,C) .
| Factors associated with postoperative CRT
On multivariable analysis, both tumor and non-tumor factors predicted the use of postoperative CRT ( Although receipt of postoperative CRT in the present study was related to pathologic risk factors, we found that variation in use was also dependent upon hospital characteristics even after controlling for pertinent pathologic risk factors. Very low volume and community hospitals tended to give more postoperative CRT, regardless of whether patients had high risk pathologic factors or no apparent risk factors. This raises the possibility that certain institutions are more likely to be "chemo-givers" despite indications to the contrary. On bivariate analyses these institutions were more likely to be community and very low volume ones; but it is apparent that specific hospitals of both types give variable amounts of postoperative CRT. It is therefore possible that unknown hospital characteristics besides volume and type account for much of the variation. These hypotheses deserve When wide variation is seen in the use of a medical service, and when guideline recommendations are not well adhered to, one explanation is that the indications-the balance of benefits and harms, remain uncertain to some practitioners. 17 The present analysis demonstrated a significant proportion of patients who did not receive postoperative CRT despite pathologic risk factors of positive margins and/or ECS. Although these risk factors were a category 1 indication during the study period in NCCN guidelines for patients to receive postoperative CRT, the significance of these factors for patients with HPV-associated disease has been brought into question. 7, [18] [19] [20] A prospective study attempts to determine the importance of ECS in this population. 21 One feature of postoperative CRT that is generally agreed upon is that patients who receive all three modalities of therapy at maximal intensity tend to suffer worse functional outcomes. 22, 23 The wide variation in use may therefore be related to lack of consensus on the benefits of and indications for postoperative CRT, specifically in HPV positive disease, and/or concern about the harms involved with tri-modal treatment.
Conversely, some practitioners may believe that there is benefit to a primary surgical approach followed by liberal provision of CRT suggests that when new data becomes available, efforts at implementation of guideline recommendations can be bolstered to ensure that practice patterns are aligned to achieve appropriate outcomes. 
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